文献速递头痛与眩晕

夫瑞奈珠单抗用于偏头痛预防治疗:无头痛日的功能状态

Fremanezumab for preventive treatment of migraine: Functional status on headache-free days.
PubMed 文献 · Neurology · 2018-08-17

本研究在2期发作性偏头痛(EM)和慢性偏头痛(CM)研究中,通过电子头痛日记前瞻性收集无头痛日的功能状态数据,评估夫瑞奈珠单抗对无头痛日功能状态的影响。结果显示,EM患者中夫瑞奈珠单抗组在全部功能指标上无头痛日且功能正常的数量较安慰剂组增加(所有p<0.005);CM患者中部分指标也有增加。

要点

  • EM患者中夫瑞奈珠单抗组在全部功能指标上无头痛日且功能正常的数量较安慰剂组增加(所有p<0.005)。
  • CM患者中夫瑞奈珠单抗组在部分功能指标上无头痛日且功能正常的数量也有增加。
  • 研究提供II级证据表明夫瑞奈珠单抗增加偏头痛患者无头痛日的正常功能表现。

核心结论

  • 夫瑞奈珠单抗治疗组中,EM患者在全部功能指标上无头痛日且功能正常的数量增加,CM患者在部分指标上增加。
  • 作者指出需要进一步的前瞻性研究来确认这些发现并阐明潜在机制。

研究设计与样本

  • 2期发作性偏头痛(EM)和慢性偏头痛(CM)研究,通过电子头痛日记前瞻性收集所有无头痛日的功能状态数据。
  • EM患者接受夫瑞奈珠单抗每月225 mg(n=96)、675 mg(n=97)或安慰剂(n=104);CM患者接受夫瑞奈珠单抗675 mg后每月225 mg(n=88)、900 mg(n=86)或安慰剂(n=89),分别独立比较。
  • 功能状态问题包括工作/学校/家务表现、工作完成速度、注意力和疲劳感。

主要发现

  • EM患者中,与安慰剂组相比,夫瑞奈珠单抗组在整个治疗期间较基线在工作/学校/家务表现和注意力/精神疲劳指标上无头痛日且功能正常的数量增加(所有p<0.005)。
  • CM患者中,夫瑞奈珠单抗组在部分功能指标上无头痛日且功能正常的数量也有增加。

关键数值与推荐

  • 研究提供II级证据表明夫瑞奈珠单抗增加偏头痛患者无头痛日的正常功能表现。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出需要进一步的前瞻性研究来确认这些发现并阐明潜在机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effect of fremanezumab on the functional status on headache-free days in phase 2 episodic migraine (EM) and chronic migraine (CM) studies. METHODS: Functional status data were collected prospectively via the electronic headache diary on all headache-free days by patients answering questions regarding work/school/household chore performance, speed of work completion, concentration, and feeling of fatigue. Individuals with EM receiving monthly doses of fremanezumab 225 mg (n = 96) or 675 mg (n = 97) or placebo (n = 104) were compared. Individuals with CM receiving fremanezumab 675 mg followed by monthly 225 mg (n = 88) and 900 mg (n = 86) were also independently compared to those receiving placebo (n = 89). RESULTS: In patients with EM, compared to patients receiving placebo, those receiving fremanezumab experienced an increased number of headache-free days with normal function in work/school/household chore performance and concentration/mental fatigue measures compared to their baseline over the entire treatment period (all p < 0.005). An increased number of headache-free days with normal functional performance for some measures was also found in the CM group in those treated with fremanezumab. CONCLUSION: There was an increased number of headache-free days with normal functional performance on all measures for the patients with EM and some measures for patients with CM in the fremanezumab-treated groups. Further research is required to confirm these findings in a prospective study and to clarify the underlying mechanism(s). CLINICALTRIALSGOV IDENTIFIER: NCT02025556 and NCT02021773. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with migraine, fremanezumab increases normal functional performance on headache-free days.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. VanderPluym J, Dodick DW, Lipton RB, et al. Fremanezumab for preventive treatment of migraine: Functional status on headache-free days. Neurology. 2018. PMID: 30120138. doi:10.1212/01.wnl.0000544321.19316.40

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。